Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Do BRAFV600E mutation and sodium-iodide symporter expression affect the response to radioactive iodine therapy in patients with papillary thyroid carcinoma?

Nuclear medicine communications - 1 May 2020

Makboul Rania, Mostafa Nadia M, El-Deek Heba E M, Aboulhagag Noha A, Shehata Mahmoud R, Abdelhafez Yasser G

Abstract excerpt

OBJECTIVE: To report on the associations between BRAF and sodium iodide symporter expressions and treatment outcomes in patients with papillary thyroid carcinoma. METHODS: Inclusion criteria included a pathologic diagnosis of papillary thyroid carcinoma of any stage, thyroidectomy followed by radioactive iodine therapy, and follow-up for at least 12 months after initial therapy. Events were classified as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iodine Radioisotopes

Share to Proto-Oncogene Proteins B-raf

Share to Recurrence

Share to Symporters

Share to Thyroid Cancer, Papillary

Share to Young Adult

Source

Identifiers

PMID: 32168263
DOI: 10.1097/MNM.0000000000001171

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Do BRAFV600E mutation and sodium-iodide symporter expression affect the response to radioactive iodine therapy in patients with papillary thyroid carcinoma?PMID 32168263Read ↗

Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.Semantic proximity Read ↗

The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.Semantic proximity Read ↗

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancerSemantic proximity Read ↗

Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapySemantic proximity Read ↗

The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer.Semantic proximity Read ↗

BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: Should we modify our therapeutic strategy?Semantic proximity Read ↗

Prognostic utility of BRAF mutation in papillary thyroid cancer.Semantic proximity Read ↗

BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine MetabolismSemantic proximity Read ↗

Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.Semantic proximity Read ↗

Association of BRAF Mutation with Treatment Response and Prognostic Factors in Papillary Thyroid Carcinoma: A Retrospective Cohort StudySemantic proximity Read ↗

Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score.Semantic proximity Read ↗

BRAF V600E Mutations in Papillary Thyroid Carcinoma: Their Relation to Clinical Features and Oncologic Outcomes in A Single Cancer Centre ExperienceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.